{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:07:28Z","timestamp":1792062448021,"version":"4.4.0"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 42267063"],"award-info":[{"award-number":["No. 42267063"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Abnormal cellular apoptosis plays a pivotal role in the pathogenesis of Multiple Myeloma (MM). Over the years, BCL-2, a crucial anti-apoptotic protein, has garnered significant attention in MM therapeutic research. Venetoclax (VTC), a small-molecule targeted agent, effectively inhibits BCL-2, promoting the programmed death of cancerous cells. While VTC has been employed to treat various hematological malignancies, its particular efficacy in MM has showcased its potential for broader clinical applications. In this review, we delve into the intricacies of how VTC modulates apoptosis in MM\u00a0cells by targeting BCL-2 and the overarching influence of the BCL-2 protein family in MM apoptosis regulation. Our findings highlight the nuanced interplay between VTC, BCL-2, and MM, offering insights that may pave the way for optimizing therapeutic strategies. Through this comprehensive analysis, we aim to lay a solid groundwork for future explorations into VTC\u2019s clinical applications and the profound effects of BCL-2 on cellular apoptosis.<\/jats:p>","DOI":"10.3389\/fphar.2023.1291920","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T15:57:17Z","timestamp":1699286237000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":51,"title":["Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review"],"prefix":"10.3389","volume":"14","author":[{"given":"Qiang","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-021-08167-y","article-title":"Intrinsic and extrinsic apoptosis responses in leukaemia cells following daunorubicin treatment","volume":"21","author":"Al-Aamri","year":"2021","journal-title":"BMC cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"869672","DOI":"10.3389\/fonc.2022.869672","article-title":"Bax\/Bcl-2 cascade is regulated by the EGFR pathway: therapeutic targeting of non-small cell lung cancer","volume":"12","author":"Alam","year":"2022","journal-title":"Front. Oncol."},{"key":"B3","volume-title":"Treatment landscape of relapsed\/refractory mantle cell lymphoma: an updated review","author":"Al-Mansour","year":"2022"},{"key":"B4","doi-asserted-by":"publisher","first-page":"106844","DOI":"10.1016\/j.leukres.2022.106844","article-title":"Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia","volume":"117","author":"Arora","year":"2022","journal-title":"Leukemia Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"107943","DOI":"10.1016\/j.pharmthera.2021.107943","article-title":"The interplay between apoptosis and cellular senescence: bcl-2 family proteins as targets for cancer therapy","volume":"230","author":"Basu","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4103\/jfmpc.jfmpc_578_19","article-title":"Trends in FDA drug approvals over last 2 decades: an observational study","volume":"9","author":"Batta","year":"2020","journal-title":"J. Fam. Med. Prim. care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1182\/blood.2021011452","article-title":"IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM","volume":"138","author":"Bazarbachi","year":"2021","journal-title":"J. Am. Soc. Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41580-020-0270-8","article-title":"Emerging connectivity of programmed cell death pathways and its physiological implications","volume":"21","author":"Bedoui","year":"2020","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/s41418-023-01187-0","article-title":"Identity, structure, and function of the mitochondrial permeability transition pore: controversies, consensus, recent advances, and future directions","volume":"30","author":"Bernardi","year":"2023","journal-title":"Cell. Death Differ."},{"key":"B10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41408-020-0320-7","article-title":"\u201cDirect to Drug\u201d screening as a precision medicine tool in multiple myeloma","volume":"10","author":"Bonolo","year":"2020","journal-title":"Blood cancer J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"9447","DOI":"10.26355\/eurrev_202212_30696","article-title":"Risk factors for the development of hepatocellular carcinoma in Chengdu: a prospective cohort study","volume":"26","author":"Cao","year":"","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7091","DOI":"10.26355\/eurrev_202210_29894","article-title":"Lung cancer screening study from a smoking population in Kunming","volume":"26","author":"Cao","year":"","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1272546","DOI":"10.3389\/fphar.2023.1272546","article-title":"A literature review: mechanisms of antitumor pharmacological action of leonurine alkaloid","volume":"14","author":"Cao","year":"","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1257638","DOI":"10.3389\/fcimb.2023.1257638","article-title":"The impact of concurrent bacterial lung infection on immunotherapy in patients with non-small cell lung cancer: a retrospective cohort study","volume":"13","author":"Cao","year":"","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1257638","DOI":"10.3389\/fcimb.2023.1257638","article-title":"The impact of concurrent bacterial lung infection on immunotherapy in patients with non-small cell lung cancer: a retrospective cohort study","volume":"13","author":"Cao","year":"","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-1-0716-2553-8_16","article-title":"Cancer and apoptosis[M]","volume-title":"Apoptosis and cancer: methods and protocols","author":"Chaudhry","year":"2022"},{"key":"B18","first-page":"1","article-title":"Venetoclax: a new partner in the novel treatment era for acute myeloid leukemia and myelodysplastic syndrome","author":"Cheikh","year":"2023","journal-title":"Clin. Hematol. Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"785855","DOI":"10.3389\/fonc.2021.785855","article-title":"Recent research progress of chiral small molecular antitumor-targeted drugs approved by the FDA from 2011 to 2019","volume":"11","author":"Chu","year":"2021","journal-title":"Front. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41580-023-00629-4","article-title":"Mechanisms of BCL-2 family proteins in mitochondrial apoptosis","volume":"24","author":"Czabotar","year":"2023","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1158\/1535-7163.MCT-20-0710","article-title":"Venetoclax-based rational combinations are effective in models of MYCN-amplified neuroblastoma","volume":"20","author":"Dalton","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"118983","DOI":"10.1016\/j.bbamcr.2021.118983","article-title":"Cancer cell death strategies by targeting Bcl-2's BH4 domain","volume":"1868","author":"de Ridder","year":"2021","journal-title":"Biochimica Biophysica Acta (BBA)-Molecular Cell. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3390\/cells8091013","article-title":"Highlights in resistance mechanism pathways for combination therapy","volume":"8","author":"Delou","year":"2019","journal-title":"Cells"},{"key":"B24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jcyt.2018.10.006","article-title":"Exosome-transmitted LINC00461 promotes multiple myeloma cell proliferation and suppresses apoptosis by modulating microRNA\/BCL-2 expression","volume":"21","author":"Deng","year":"2019","journal-title":"Cytotherapy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","article-title":"The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs","volume":"22","author":"Diepstraten","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.14740\/jh844","article-title":"Role of Venetoclax in the treatment of relapsed and refractory multiple myeloma","volume":"10","author":"Ehsan","year":"2021","journal-title":"J. Hematol."},{"key":"B27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/9783527814695.ch9","article-title":"Discovery and development of Venetoclax, a selective antagonist of BCL\u20102","volume":"4","author":"Fairbrother","year":"2019","journal-title":"Success. drug Discov."},{"key":"B28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00428-022-03431-3","article-title":"Plasma cell neoplasms and related entities\u2014evolution in diagnosis and classification","volume":"482","author":"Fend","year":"2023","journal-title":"Virchows Arch."},{"key":"B29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021","journal-title":"Cancers"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/cam4.3665","article-title":"225Ac\u2010labeled CD33\u2010targeting antibody reverses resistance to Bcl\u20102 inhibitor venetoclax in acute myeloid leukemia models","volume":"10","author":"Garg","year":"2021","journal-title":"Cancer Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1123029","DOI":"10.3389\/fonc.2023.1123029","article-title":"Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories","volume":"13","author":"Gkoliou","year":"2023","journal-title":"Front. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood-2020-140581","article-title":"In vivo pre-clinical evaluation of LOXO-305 alone and in combination with venetoclax, rituximab, R-CHOP or obinutuzumab on human xenograft lymphoma tumor models in mice","volume":"136","author":"Gomez","year":"2020","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3390\/cancers15020510","article-title":"Concurrent inhibition of akt and ERK using TIC-10 can overcome venetoclax resistance in mantle cell lymphoma","volume":"15","author":"Granau","year":"2023","journal-title":"Cancers"},{"key":"B34","doi-asserted-by":"publisher","first-page":"a041046","DOI":"10.1101\/cshperspect.a041046","article-title":"The mitochondrial pathway of apoptosis Part II: the BCL-2 protein family","volume":"14","author":"Green","year":"2022","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cca.2019.12.026","article-title":"Emerging biomarkers in multiple myeloma: a review","volume":"503","author":"Gupta","year":"2020","journal-title":"Clin. Chim. acta"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"J. Am. Soc. Hematol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12964-023-01247-5","article-title":"Regulation of anoikis by extrinsic death receptor pathways","volume":"21","author":"Han","year":"2023","journal-title":"Cell. Commun. Signal."},{"key":"B38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-142054","article-title":"Efficacy of venetoclax based regimens in relapsed refractory multiple myeloma: a systematic review and meta-analysis","volume":"136","author":"Hashim","year":"2020","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1159\/000520312","article-title":"Multiple myeloma: molecular pathogenesis and disease evolution","volume":"44","author":"Heider","year":"2021","journal-title":"Oncol. Res. Treat."},{"key":"B40","doi-asserted-by":"publisher","first-page":"212574","DOI":"10.7573\/dic.212574","article-title":"Venetoclax: evidence to date and clinical potential","volume":"8","author":"Ju\u00e1rez-Salcedo","year":"2019","journal-title":"Drugs context"},{"key":"B41","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s43018-023-00571-6","article-title":"Non-lethal outcomes of engaging regulated cell death pathways in cancer","volume":"4","author":"Kalkavan","year":"2023","journal-title":"Nat. Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","article-title":"BCL-2 protein family: attractive targets for cancer therapy","volume":"28","author":"Kaloni","year":"2023","journal-title":"Apoptosis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell. death Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1080\/17474086.2020.1756258","article-title":"Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond","volume":"13","author":"Kocoglu","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41419-021-04079-8","article-title":"Importance of Bcl-2-family proteins in murine hematopoietic progenitor and early B cells","volume":"12","author":"Kurschat","year":"2021","journal-title":"Cell. Death Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/jpm11060463","article-title":"Review of venetoclax in CLL, AML and multiple myeloma","volume":"11","author":"Lasica","year":"2021","journal-title":"J. personalized Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fphar.2019.00697","article-title":"Efficacy and safety of Bcl-2 inhibitor venetoclax in hematological malignancy: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Li","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1005659","DOI":"10.3389\/fonc.2022.1005659","article-title":"Mechanisms of venetoclax resistance and solutions","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41467-022-28741-7","article-title":"Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer","volume":"13","author":"Lopez","year":"2022","journal-title":"Nat. Commun."},{"key":"B50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1042\/BCJ20210854","article-title":"The concept of intrinsic versus extrinsic apoptosis","volume":"479","author":"Lossi","year":"2022","journal-title":"Biochem. J."},{"key":"B51","first-page":"341","article-title":"Immunoglobulin D-lambda multiple myeloma, and a review of the literature","volume":"8","author":"Maataoui","year":"2021","journal-title":"Clin. Med. Rev. Case Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3390\/biomedicines11061666","article-title":"Simultaneous inhibition of mcl-1 and bcl-2 induces synergistic cell death in hepatocellular carcinoma","volume":"11","author":"Michalski","year":"2023","journal-title":"Biomedicines"},{"key":"B53","doi-asserted-by":"publisher","first-page":"7627","DOI":"10.3390\/ijms23147627","article-title":"Targeting the microenvironment for treating multiple myeloma","volume":"23","author":"Neumeister","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41698-022-00315-2","article-title":"Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t (11; 14)","volume":"6","author":"Nguyen","year":"2022","journal-title":"NPJ Precis. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood.2020008608","article-title":"Venetoclax and ibrutinib for patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"137","author":"Niemann","year":"2021","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/14740338.2021.1890023","article-title":"A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis","volume":"20","author":"Nuvolone","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"B57","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14737140.2020.1708721","article-title":"Limited treatment options in refractory multiple myeloma: promising therapeutic developments","volume":"20","author":"Oriol","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"119047","DOI":"10.1016\/j.bbamcr.2021.119047","article-title":"Targeting epigenetic mechanisms to overcome venetoclax resistance","volume":"1868","author":"Prado","year":"2021","journal-title":"Biochimica Biophysica Acta (BBA)-Molecular Cell. Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"985363","DOI":"10.3389\/fonc.2022.985363","article-title":"The role of BCL-2 family proteins in regulating apoptosis and cancer therapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front. Oncol."},{"key":"B60","first-page":"1187","article-title":"Mechanisms of p2x7 receptor involvement in pain regulation: a literature review","volume":"38","author":"Qiang","year":"2022","journal-title":"Acta Medica Mediterr."},{"key":"B61","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10495-020-01601-9","article-title":"BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy","volume":"25","author":"Ramesh","year":"2020","journal-title":"Apoptosis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4155\/bio-2021-0207","article-title":"LC\u2013MS\/MS bioanalytical method for quantification of binimetinib and venetoclax, and their pharmacokinetic interaction","volume":"14","author":"Reddy","year":"2021","journal-title":"Bioanalysis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41419-020-02867-2","article-title":"Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition","volume":"11","author":"Roca-Portoles","year":"2020","journal-title":"Cell. death Dis."},{"key":"B64","doi-asserted-by":"publisher","first-page":"188791","DOI":"10.1016\/j.bbcan.2022.188791","article-title":"Modulation of Ca2+ signaling by antiapoptotic Bcl-2 versus Bcl-xL: from molecular mechanisms to relevance for cancer cell survival","volume":"1877","author":"Rosa","year":"2022","journal-title":"Biochimica Biophysica Acta (BBA)-Reviews Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s12325-021-01919-z","article-title":"Population pharmacokinetics and exposure\u2013response analyses for venetoclax in combination with R-CHOP in relapsed\/refractory and previously untreated patients with diffuse large B cell lymphoma","volume":"39","author":"Samineni","year":"2022","journal-title":"Adv. Ther."},{"key":"B66","doi-asserted-by":"publisher","first-page":"175588","DOI":"10.1016\/j.ejphar.2023.175588","article-title":"Therapeutic advancements in targeting BCL-2 family proteins by epigenetic regulators, natural, and synthetic agents in cancer","volume":"944","author":"Sarkar","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13543784.2020.1760245","article-title":"Novel agents for mantle cell lymphoma: molecular rational and clinical data","volume":"29","author":"Sarkozy","year":"2020","journal-title":"Expert Opin. Investigational Drugs"},{"key":"B68","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/13543784.2020.1789588","article-title":"Enhancing venetoclax activity in hematological malignancies","volume":"29","author":"Satta","year":"2020","journal-title":"Expert Opin. investigational drugs"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3390\/biom10121638","article-title":"The mysteries around the BCL-2 family member BOK","volume":"10","author":"Shalaby","year":"2020","journal-title":"Biomolecules"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3324\/haematol.2021.279276","article-title":"Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment","volume":"107","author":"Soncini","year":"2022","journal-title":"Haematologica"},{"key":"B71","doi-asserted-by":"publisher","first-page":"172655","DOI":"10.1016\/j.ejphar.2019.172655","article-title":"Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy","volume":"862","author":"Suvarna","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S2352-3026(19)30253-4","article-title":"Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations","volume":"7","author":"Tambaro","year":"2020","journal-title":"Lancet Haematol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s11357-022-00698-x","article-title":"Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment","volume":"45","author":"Urban","year":"2023","journal-title":"GeroScience"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13265","article-title":"Antibody\u2010mediated phagocytosis in cancer immunotherapy","author":"Van Wagoner","year":"2023","journal-title":"Immunol. Rev."},{"key":"B75","doi-asserted-by":"publisher","first-page":"4847","DOI":"10.1182\/bloodadvances.2022007364","article-title":"Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis","volume":"6","author":"Vogiatzi","year":"2022","journal-title":"Blood Adv."},{"key":"B76","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00277-020-03911-z","article-title":"Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax","volume":"99","author":"Wang","year":"2020","journal-title":"Ann. Hematol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv."},{"key":"B78","doi-asserted-by":"publisher","first-page":"12732","DOI":"10.3390\/ijms232112732","article-title":"Antimicrobial peptides mediate apoptosis by changing mitochondrial membrane permeability","volume":"23","author":"Wang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"J. Am. Soc. Hematol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1268188","DOI":"10.3389\/fimmu.2023.1268188","article-title":"Reprogramming of treg cells in the inflammatory microenvironment during immunotherapy: a literature review","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"154715","DOI":"10.1016\/j.prp.2023.154715","article-title":"Decoding the role of miRNAs in multiple myeloma pathogenesis: a focus on signaling pathways","volume":"248","author":"Yehia","year":"2023","journal-title":"Pathology-Research Pract."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1186\/s12889-023-16358-4","article-title":"Mitigation role of physical exercise participation in the relationship between blood cadmium and sleep disturbance: a cross-sectional study","volume":"23","author":"You","year":"2023","journal-title":"BMC Public Health"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-020-01614-z","article-title":"Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies","volume":"20","author":"Yue","year":"2020","journal-title":"Cancer Cell. Int."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"J. Am. Soc. Hematol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"188569","DOI":"10.1016\/j.bbcan.2021.188569","article-title":"Targeting Bcl-2 for cancer therapy","volume":"1876","author":"Zhang","year":"2021","journal-title":"Biochimica Biophysica Acta (BBA)-Reviews Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s13018-022-03271-6","article-title":"Safety and risk factors of TINAVI robot-assisted percutaneous pedicle screw placement in spinal surgery","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell. Death Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1291920\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T15:57:24Z","timestamp":1699286244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1291920\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":87,"alternative-id":["10.3389\/fphar.2023.1291920"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1291920","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]},"article-number":"1291920"}}